GlassScriptPhysician profile
Sarah E Schuller
NPI 1407463292
$11,720.44
in general payments reported to CMS, 2019-2025
24 companies · $3,206 in 2025
The $3,206 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,458 · 2022: $1,673 · 2023: $2,430 · 2024: $2,955 · 2025: $3,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,583 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,582.67 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,895.42 | 2021-2025 | Spravato, Invega Sustenna, Invega |
| Abbvie INC. | $1,864.04 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,149.94 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $856.64 | 2021-2025 | Caplyta |
| Lundbeck LLC | $837.22 | 2021-2025 | Rexulti, Brintellix |
| Corium, LLC | $766.32 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $763.54 | 2021-2025 | Qelbree, Qelbree |
| Neuronetics, INC. | $476.02 | 2021-2024 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $423.41 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $388.67 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $337.09 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $309.57 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $307.11 | 2022-2024 | Jornay Pm |
| Mdd US Operations, LLC | $214.10 | 2025 | Qelbree |
| Tris Pharma INC | $196.73 | 2023-2025 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $182.56 | 2025 | Cobenfy |
| Alkermes, INC. | $174.08 | 2022-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $144.69 | 2022-2025 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $113.53 | 2023-2025 | Loreev Xr |
| Itamar Medical INC | $109.43 | 2024-2025 | Watchpatone |
| Collegium Pharmaceutical, INC. | $68.14 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $54.05 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $51.72 | 2024 | Xelstrym, Secuado |
| Biogen, INC. | $36.42 | 2024-2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Schuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.